MedTrace Logo

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

NCT04322227 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-07-07

No results posted yet for this study

Summary

The purpose of this study is to investigate effects of foliglurax on brain wave patterns (electric signals) in healthy subjects and in patients with PD

Conditions

  • Parkinson Disease
  • Healthy

Interventions

DRUG

Foliglurax 10 mg (treatment A)

Foliglurax 10 mg, (BID) capsules, orally

DRUG

Foliglurax 30 mg (treatment B)

Foliglurax 30 mg, BID capsules, orally

DRUG

Placebo (treatment C)

Placebo, BID capsules, orally

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-23
Primary Completion
2020-05-30
Completion
2020-05-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322227 on ClinicalTrials.gov